Suppr超能文献

在结合疫苗时代儿童感染肺炎链球菌和乙型流感嗜血杆菌疾病的负担:2000-2015 年全球、区域和国家估计数。

Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15.

机构信息

International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

出版信息

Lancet Glob Health. 2018 Jul;6(7):e744-e757. doi: 10.1016/S2214-109X(18)30247-X.

Abstract

BACKGROUND

Pneumococcal conjugate vaccine (PCV) and Haemophilus influenzae type b (Hib) vaccine are now used in most countries. To monitor global and regional progress towards improving child health and to inform national policies for disease prevention and treatment, we prepared global, regional, and national disease burden estimates for these pathogens in children from 2000 to 2015.

METHODS

Using WHO and Maternal and Child Epidemiology Estimation collaboration country-specific estimates of pneumonia and meningitis mortality and pneumonia morbidity from 2000 to 2015, we applied pneumococcal and Hib cause-specific proportions to estimate pathogen-specific deaths and cases. Summary estimates of the proportion of pneumonia deaths and cases attributable to these pathogens were derived from four Hib vaccine and six PCV efficacy and effectiveness study values. The proportion of meningitis deaths due to each pathogen was derived from bacterial meningitis aetiology and adjusted pathogen-specific meningitis case-fatality data. Pneumococcal and Hib meningitis cases were inferred from modelled pathogen-specific meningitis deaths and literature-derived case-fatality estimates. Cases of pneumococcal and Hib syndromes other than pneumonia and meningitis were estimated using the ratio of pathogen-specific non-pneumonia, non-meningitis cases to pathogen-specific meningitis cases from the literature. We accounted for annual HIV infection prevalence, access to care, and vaccine use.

FINDINGS

We estimated that there were 294 000 pneumococcal deaths (uncertainty range [UR] 192 000-366 000) and 29 500 Hib deaths (18 400-40 700) in HIV-uninfected children aged 1-59 months in 2015. An additional 23 300 deaths (15 300-28 700) associated with pneumococcus and fewer than 1000 deaths associated Hib were estimated to have occurred in children infected with HIV. We estimate that pneumococcal deaths declined by 51% (7-74) and Hib deaths by 90% (78-96) from 2000 to 2015. Most children who died of pneumococcus (81%) and Hib (76%) presented with pneumonia. Less conservative assumptions result in pneumococcccal death estimates that could be as high as 515 000 deaths (302 000-609 000) in 2015. Approximately 50% of all pneumococcal deaths in 2015 occurred in four countries in Africa and Asia: India (68 700 deaths, UR 44 600-86 100), Nigeria (49 000 deaths, 32 400-59 000), the Democratic Republic of the Congo (14 500 deaths, 9300-18 700), and Pakistan (14 400 deaths, 9700-17 000]). India (15 600 deaths, 9800-21 500), Nigeria (3600 deaths, 2200-5100), China (3400 deaths, 2300-4600), and South Sudan (1000 deaths, 600-1400) had the greatest number of Hib deaths in 2015. We estimated 3·7 million episodes (UR 2·7 million-4·3 million) of severe pneumococcus and 340 000 episodes (196 000-669 000) of severe Hib globally in children in 2015.

INTERPRETATION

The widespread use of Hib vaccine and the recent introduction of PCV in countries with high child mortality is associated with reductions in Hib and pneumococcal cases and deaths. Uncertainties in the burden of pneumococcal disease are largely driven by the fraction of pneumonia deaths attributable to pneumococcus. Progress towards further reducing the global burden of Hib and pneumococcal disease burden will depend on the efforts of a few large countries in Africa and Asia.

FUNDING

Bill & Melinda Gates Foundation.

摘要

背景

目前,大多数国家都在使用肺炎球菌结合疫苗(PCV)和流感嗜血杆菌疫苗(Hib)。为了监测在改善儿童健康方面取得的全球和区域进展,并为疾病预防和治疗提供国家政策信息,我们针对这些病原体在儿童中的疾病负担进行了全球、区域和国家层面的估算,估算时间为 2000 年至 2015 年。

方法

我们利用世卫组织和母婴与儿童流行病学估算合作组织针对肺炎和脑膜炎死亡率以及 2000 年至 2015 年期间肺炎发病率的国家特异性估计数,应用肺炎球菌和 Hib 病因特异性比例来估算病原体特异性死亡和病例。通过四项 Hib 疫苗和六项 PCV 功效和效果研究值得出肺炎死亡和病例归因于这些病原体的比例的综合估计数。根据细菌性脑膜炎病因学和调整后的病原体特异性脑膜炎病死率数据,推导出每种病原体导致的脑膜炎死亡比例。从模型化的病原体特异性脑膜炎死亡数据和文献中得出的病死率估算数据中推断出肺炎球菌和 Hib 脑膜炎病例。通过文献中病原体特异性非肺炎和非脑膜炎病例与脑膜炎病例的比例来估算肺炎球菌和 Hib 综合征以外的其他病例。我们考虑了每年艾滋病毒感染率、获得医疗保健服务的机会和疫苗接种情况。

结果

我们估计,2015 年在无艾滋病毒感染的 1 至 59 月龄儿童中,有 294000 例肺炎球菌死亡(不确定范围[UR]为 192000 例至 366000 例)和 29500 例 Hib 死亡(18400 例至 40700 例)。在感染艾滋病毒的儿童中,我们估计还发生了与肺炎球菌相关的 23300 例(15300 例至 28700 例)额外死亡和少于 1000 例与 Hib 相关的死亡。我们估计,从 2000 年至 2015 年,肺炎球菌死亡下降了 51%(7%至 74%),Hib 死亡下降了 90%(78%至 96%)。我们估计,大多数死于肺炎球菌(81%)和 Hib(76%)的儿童患有肺炎。如果采用较为保守的假设,肺炎球菌死亡的估算值可能高达 2015 年的 515000 例(302000 例至 609000 例)。2015 年,非洲和亚洲的四个国家发生了近一半的所有肺炎球菌死亡:印度(68700 例死亡,UR 44600 例至 86100 例)、尼日利亚(49000 例死亡,32400 例至 59000 例)、刚果民主共和国(14500 例死亡,9300 例至 18700 例)和巴基斯坦(14400 例死亡,9700 例至 17000 例)。印度(15600 例死亡,9800 例至 21500 例)、尼日利亚(3600 例死亡,2200 例至 5100 例)、中国(3400 例死亡,2300 例至 4600 例)和南苏丹(1000 例死亡,600 例至 1400 例)在 2015 年发生了最多的 Hib 死亡。我们估计,2015 年全球有 370 万例(UR 270 万例至 430 万例)严重肺炎球菌病例和 34 万例(UR 19.6 万例至 66.9 万例)严重 Hib 病例。

解释

广泛使用 Hib 疫苗和在高儿童死亡率国家中最近引入 PCV 与 Hib 和肺炎球菌病例和死亡的减少有关。肺炎球菌疾病负担的不确定性主要是由肺炎死亡归因于肺炎球菌的比例所驱动。要进一步减少非洲和亚洲几个大国的 Hib 和肺炎球菌疾病负担,取决于它们的努力。

资助

比尔及梅琳达·盖茨基金会。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e768/6005122/59176af0f832/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验